Latest News

We would like to bring to your attention the upcoming Cell Symposium: Human Genomics, organized by Huck Hui Ng (A*Star), Steve Mao (Cell), and Sabbi Lall (Cell Reports).We are very excited for this symposium, held in partnership with A*Star in Singapore, November 8-10, 2015.

The Genomic Medicine Alliance has joined this week, as Organizational member, the Global Alliance for Genomics and Health.

The Global Alliance for Genomics and Health aims to help accelerate the potential of genomic medicine to advance human health.The Global Alliance works to establish, broadly disseminate, and advocate for the use of interoperable technical standards for managing and sharing genomic and clinical data. At present, the Global Alliance brings together over 220 leading institutions working in healthcare, research, disease advocacy, life science, and information technology that are working together to create a common framework of harmonized approaches to enable the responsible, voluntary, and secure sharing of genomic and clinical data.

By partnering with the Global Alliance, the Genomic Medicine Alliance aims to create synergies for the benefit of its members, particularly from developing countries, where genomics data sharing is still in its infancy.

The 16th Golden Helix Pharmacogenomics Day is an educational event that aims to provide timely updates on the field of pharmacogenomics and personalized medicine to the local biomedical scientists and healthcare providers, to inform them on the application of pharmacogenomics in fields such as psychiatric disorders, oncology, and to bring together faculty members from universities and research institutes from the local scientific arena working in the field of pharmacogenomics in order to initiate collaborative projects in this field to the benefit of society.

This workshop will include:

• Lectures by 6 speakers from the US, both from academia, industry and regulatory (NIH) backgrounds.
• Topics will pertain to pharmacogenomics and personalized medicine
• The Global Genomic Medicine Collaborative and the Genomic Medicine Alliance initiatives will be highlighted.

What will participants take away from this workshop?

• The most recent trends on pharmacogenomics
• The aims and goals of the Global Genomic Medicine Collaborative and the Genomic Medicine Alliance Initiatives
• Collaboration and training opportunities with the faculty of the workshop

Organizing committee

George P. Patrinos, University of Patras Department of Pharmacy, Patras, Greece

Konstantinos Mitropoulos, the Golden Helix Foundation, London, UK

Speakers:

• Teri Manolio, Director, Division of Genomic Medicine, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
• Federico Innocenti, Associate Professor, University of North Carolina, Chapel Hill, NC, USA
• Alan R. Shuldiner, Vice President, Translational Genetics, Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
• Marc S. Williams, Director, Genomic Medicine Institute, Geisinger Health System, Danville, PA,USA
• George P. Patrinos, Associate Professor, University of Patras Department of Pharmacy, Patras, Greece
• Deepak Voora, Assistant Professor, Duke Center for Genomic and Computational Biology, Durham, NC, USA

Enter promo code: Helix25 and get 25% off at registration.

The Genomic Medicine Alliance proudly announces the publication of the Special Issue with the theme "Public Health Pharmacogenomics", guest edited by Professor George P. Patrinos (University of Patras, Greece) and published by Public Health Genomics, the official journal of the Genomic Medicine Alliance.

Pharmacogenomics has a pivotal role in genomic medicine aiming to delineate drug efficacy and toxicity with the underlying genomic composition in genes involved in the pharmacokinetics and pharmacodynamics of drug regimens. Although there have been major leaps in pharmacogenomic research, facilitated by the genomic technology revolution, the pace of these discoveries have not met with reciprocal advances in the translation of these findings into the clinic, resulting into the personalization of conventional therapeutic interventions. To this end, there are often significant barriers that hamper the smooth incorporation of pharmacogenomics research findings in the daily medical practice, which have to do more with disciplines related to Public Health Genomics rather than pharmacogenomics research itself.

This Special issue is a collection of timely contributions of perspectives and original articles that touch upon pharmacogenomics in relation to Public Health Genomics disciplines, namely ethics in genomics, economic evaluation in genomic medicine, genome informatics and knowledgebases, and the involvement and genetics education of the various stakeholders in the field of pharmacogenomics.

To access the full content of the Special Issue "Public Health Pharmacogenomics", please click here.